Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of bendamustine + bortezomib + dexamethasone in elderly patients with relapsed or refractory multiple myeloma
2009-012359-91Phase 2Active
- Sponsor
- Inter-Groupe Francophone du Myélome
- Start
- Aug 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine, bortezomib and dexamethasone in multiple myeloma (MM), sponsored by Inter-Groupe Francophone du Myélome. Primary endpoint: Overall response rate. Started Aug 2009; status: active.
02
Drugs
bendamustinebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2009-012359-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012359-91.